Carmot Therapeutics Inc. (CRMO)

Carmot Therapeutics was planning to go public, but the IPO was withdrawn on Dec 11, 2023.
Stock Price: Pending
IPO price not available yet
Chart not available yet
Data will show when the stock starts trading.
Market Capn/a
Revenue (ttm)n/a
Net Income (ttm)-51.69M
Shares Out n/a
EPS (ttm)n/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Openn/a
Previous Closen/a
Day's Rangen/a
52-Week Rangen/a
Betan/a
Analystsn/a
Price Targetn/a
Earnings Daten/a

About CRMO

Carmot Therapeutics is a clinical-stage biotechnology company dedicated to developing life-changing therapeutics for people living with metabolic diseases including obesity and diabetes. We are developing our broad, wholly-owned pipeline of novel incretin agonists, using our Chemotype Evolution platform, with the potential to address these shortcomings and produce significant weight loss and glycemic control. Our patient-focused portfolio has the potential to provide differentiated solutions for every patient’s individual metabolic health journ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 59
Stock Exchange NASDAQ
Ticker Symbol CRMO
Full Company Profile

Financial Performance

Financial Statements

News

Carmot Therapeutics IPO Registration Document (S-1)

Carmot Therapeutics has filed to go public with an IPO on the NASDAQ.

1 year ago - SEC

Carmot Therapeutics Commenced Phase 2 Clinical Trial of Novel Dual GLP-1/GIP Receptor Agonist CT-868 for the Treatment of Type 1 Diabetes

Randomized, placebo-controlled trial to assess 16-week treatment with CT-868 in participants with overweight or obesity with type 1 diabetes (T1D)

1 year ago - EIN Presswire